One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
Authors' conclusion
In this retrospective cohort study of 3389 patients with obesity, weight reduction at 1 year was associated with the medication's active agent, its dosage, treatment indication, persistent medication coverage, and patient sex. Future research should focus on identifying the reasons for discontinuation of medication use and interventions aimed at improving long-term persistent coverage.
Study context
- Population
- Adults with BMI ≥30.0 initiating semaglutide or liraglutide, July 1, 2015–June 30, 2022, large integrated health system in Ohio and Florida; mean (SD) age 50.4 (12.2) years, 54.7% female
- Participants
- 3,389 adults
- Exposure
- Semaglutide vs liraglutide for T2D or obesity
- Outcome
- Percentage weight change and categorical weight reduction of 10% or greater
- Follow-up
- 1 year
Methodological detailselectronic health records, integrated health system, Follow-up completed July 28, 2023
- Electronic health records
- Integrated health system
- Follow-up completed July 28, 2023
Main finding
Percentage weight change
AOR for ≥10% weight reduction
2.19
95% CI 1.77–2.72
P < 0.001
Change by group
Semaglutide
−5.1%
mean · SD 7.8%
Liraglutide
−2.2%
mean · SD 6.4%
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Values | Estimate | P value | |
|---|---|---|---|---|
| Percentage weight change by treatment indication · 1 yearObesityvs T2DP refers to percentage weight change comparison | T2D mean −3.2% (SD 6.8%) · Obesity mean −5.9% (SD 9.0%) | AOR for ≥10% weight reduction 2.46 (95% CI 1.83–3.30) | P < 0.001 | |
| Percentage weight change by medication coverage · 1 yearPersistent coverage (gap <90 days)vs <90 coverage days | Persistent coverage (gap <90 days) mean −5.5% (SD 7.5%) · 90 to 275 coverage days mean −2.8% (SD 7.0%) · <90 coverage days mean −1.8% (SD 6.7%) | AOR for ≥10% weight reduction 3.36 (95% CI 2.52–4.54) | P < 0.001 | |
| Percentage weight change by medication coverage · 1 year90 to 275 coverage daysvs <90 coverage days | AOR for ≥10% weight reduction 1.50 (95% CI 1.10–2.06) | |||
| ≥10% weight reduction at 1 year: dosage and sexHigh dosagevs Low dosageMultivariable model | AOR 1.58 (95% CI 1.11–2.25) | |||
| 0.20.5125Ratio (log scale) |
≥10% weight reduction at 1 year: dosage and sex
| AOR (95% CI) | ||
|---|---|---|
| FemaleMultivariable model | 1.57 (1.27–1.94) | |
| 0.512Adjusted odds ratio (log scale) |
- Percentage weight change by medication coverage: P refers to percentage weight change comparison across coverage groups
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →